tickrz reports
tickrz rank
D
Eli Lilly and Co (LLY)
Healthcare | Drugs
82.91  -0.66%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 402Warren Buffett RankB / 240
Pure Value RankD / 414Dividend RankD / 377
Moat RankC / 238Financial Strength RankB / 116
Growth RankD / 409Momentum RankC / 306
LLY vs DRUGS SECTOR & S&P 500
VALUATION
LLYSECTORS&P 500
P/E RATIO39.5437.819.7
EV/EBITDA RATIO20.53125.211.95
P/S RATIO3.916.22.08
P/B RATIO5.917.33.18
QUALITY
RETURN ON EQUITY14.55%15.79%13.65%
RETURN ON CAPITAL14.26%18.8%10.2%
NET MARGIN12.9%14.46%9.75%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.49%
PAYOUT RATIO98.22%
3 YR DIVIDEND GROWTH1.34%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY90%
INTEREST COVERAGE16.62x
CURRENT RATIO1.38
GROWTH
5 YR EPS GROWTH-7.93%
5 YR SPS GROWTH-2.66%
5 YR BPS GROWTH1.7%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank D / 402
Eli Lilly and Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 414Warren Buffett ranking B / 240
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Eli Lilly and Co's valuation score is comprised of a P/E ratio of 39.5x, a P/B ratio of 5.9x, a P/S ratio of 3.9x, and an EV/EBITDA ratio of 20.5x. Eli Lilly and Co ranks 414 out of the S&P 500 constituents on valuation--a relatively weak score.Eli Lilly and Co ranks 240 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Eli Lilly and Co is probably not for you.

quality
moat C / 238financial strength B / 116
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Eli Lilly and Co has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 16.62x, a debt/equity ratio of 90% and a Moat Rank of 238 translate to an average Financial Strength score.


momentum C / 306
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 9.98% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 306. Based on its 12 month stock performance, Eli Lilly and Co will not appeal to momentum investors.

yield D / 377
value + yield
Shares currently yield 2.49%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Eli Lilly and Co ranks 377 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 409
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -7.9% 5 year annualized EPS growth, -2.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% speak to its relatively poor ranking.

Eli Lilly and Co (LLY)
Healthcare | Drugs
82.91  -0.66%


tickrz rank
D
VALUATION RATIOS
P/E Ratio39.54x
P/B Ratio5.91x
P/S Ratio3.91x
EV/EBITDA Ratio20.53x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.49%
PAYOUT RATIO98.22%
3 YR DIVIDEND GROWTH1.34%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY90%
INTEREST COVERAGE16.62x
CURRENT RATIO1.38
MOAT
ROE14.55%
ROIC14.26%
Net Margin12.9%
GROWTH
5 YR EPS GROWTH-7.93%
5 YR SPS GROWTH-2.66%
5 YR BPS GROWTH1.7%

TICKRZ RANK
Eli Lilly and Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Eli Lilly and Co's valuation score is comprised of a P/E ratio of 39.5x, a P/B ratio of 5.9x, a P/S ratio of 3.9x, and an EV/EBITDA ratio of 20.5x. Eli Lilly and Co ranks 414 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Eli Lilly and Co ranks 240 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Eli Lilly and Co is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Eli Lilly and Co has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 16.62x, a debt/equity ratio of 90% and a Moat Rank of 238 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 9.98% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 306. Based on its 12 month stock performance, Eli Lilly and Co will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.49%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Eli Lilly and Co ranks 377 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -7.9% 5 year annualized EPS growth, -2.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% speak to its relatively poor ranking.